Vertex Pharmaceuticals Incorporated

Total Valuation

Vertex Pharmaceuticals Incorporated carries a market capitalization of 138.61B, placing it among publicly traded companies globally. Its enterprise value stands at 119.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Vertex Pharmaceuticals Incorporated currently has 253.35M shares outstanding.

Valuation Ratios

Vertex Pharmaceuticals Incorporated trades at a trailing price-to-earnings ratio of 28.68. The price-to-sales ratio is 10.04, and the price-to-book ratio stands at 6.22.

Enterprise Valuation

On an enterprise value basis, Vertex Pharmaceuticals Incorporated trades at an EV/EBITDA multiple of 24.00 and an EV/FCF ratio of 25.02. The EV/Sales ratio of 9.53 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.12 provides insight into valuation relative to core operating earnings.

Financial Position

Vertex Pharmaceuticals Incorporated maintains a current ratio of 3.19, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.77, indicating elevated leverage, while an interest coverage ratio of 757.38 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Vertex Pharmaceuticals Incorporated posts a return on equity of 23.54 and a return on invested capital of 19.49.

Taxes

Over the trailing twelve months, Vertex Pharmaceuticals Incorporated has paid 869.30M in income taxes, reflecting an effective tax rate of 16.48.

Stock Price Statistics

Vertex Pharmaceuticals Incorporated's stock has gained approximately 37.86731% over the past 52 weeks. The 50-day moving average sits at 508.76, while the 200-day moving average is 466.15.

Income Statement

Over the trailing twelve months, Vertex Pharmaceuticals Incorporated generated 12.59B in revenue and converted that into 4.41B in net income, yielding earnings per share of 17.19. EBITDA reached 5.00B, while operating income came in at 4.78B.

Balance Sheet

Vertex Pharmaceuticals Incorporated holds 7.85B in cash and equivalents against 1.98B in total debt, resulting in a net debt position of -6.14B. Total book value stands at 20.25B, with working capital of 8.61B providing operational flexibility.

Cash Flow

Vertex Pharmaceuticals Incorporated produced 4.29B in operating cash flow over the past twelve months. After subtracting -496.80M in capital expenditures, free cash flow totaled 3.80B - equivalent to 14.93 per share.

Margins

Vertex Pharmaceuticals Incorporated operates with a gross margin of 86.00, reflecting its pricing power and cost economics. The operating margin of 37.95 and net profit margin of 35.00 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Vertex Pharmaceuticals Incorporated's most recent stock split took place on August 24, 2000 with a 1:2 split ratio.

Scores

Vertex Pharmaceuticals Incorporated posts an Altman Z-Score of 12.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.